Warner-Lambert v. Kent - Transcript Of Oral Argument
The court reporters were a little late today, but the oral argument transcript for Warner-Lambert v. Kent is now available. Compare your impressions to those of our intrepid correspondent.
1 comment:
Henry Greenspan, Ph.D.
said...
Small point - However the USC decides Kent, Michigan's so-called "fraud exception" was meaningless. As worded, it requires both (a) a finding of intentional (e.g., felony) misrepresentation and (b) drug withdrawal directly linked with that finding.
There has not been a single case in the past twenty-five years that meets both criteria. As FDA's own amicus emphasizes in Kent, FDA favors a wide range of responses when fraud is suspected or fully uncovered - settling with company through a monetary fine and without pursuing prosecution, a label change, or some sort of warning/remedial program. None of these circumstances satisfy either condition. Nor (obviously) do they satisfy both.
As is well known, there is also a "would have been withdrawn" phrasing in Michigan's law had the intentional suppressed or mispresented facts been known. This bit is definitively impossible to litigate since no agency knows, or has a body which could decide, what it "would have done" under X, Y, Z circumstances. Thus, the writers of the Michigan law - whatever else one may say - were not the brightest bulbs in the state. FDA's inability to determine what it "might have done" - as well as its disinclination to be a "gatekeeper" to civil action - is also much emphasized in its amicus.
Thus, this decision is much more likely to impact fraud findings in states in which state court findings of fraud are a condition for punitive damages - famously, New Jersey - than Michigan.
This blog contains JIM BECK's personal views (and those of several other attorneys) of various topics that arise in the defense of pharmaceutical and medical device product liability litigation. Please read the DISCLAIMER about the nature of this blog, and understand that you are accepting its terms, before reading any of our posts.
Blogging Team
James M. Beck is Counsel resident in the Philadelphia office of Reed Smith. He is the author of, among other things, Drug and Medical Device Product Liability Handbook (2004) (with Anthony Vale). he wrote the seminal law review article on off-label use cited by the Supreme Court in Buckman v. Plaintiffs Legal Committee. He has written more amicus briefs for the Product Liability Advisory Council than anyone else in the history of the organization, and in 2011 won PLAC's highest honor, the John P. Raleigh award. He can be reached at jmbeck@reedsmith.com.
Stephen McConnell has authored articles and chapters on product liability (though nothing as snappy or authoritative as Beck's book) and has tried drug and device cases that managed to evade the pretrial gauntlet. He is a partner in the Philadelphia office of Reed Smith and can be reached at smcconnell@reedsmith.com.
Michelle Hart Yeary is a seasoned products liability litigator who focuses on attempting to bring order to the chaos that is mass torts, concentrating on the practicalities and realities of defending coordinated and multidistrict litigation. She is counsel in the Princeton office of Dechert LLP and can be reached at michelle.yeary@dechert.com.
John J. Sullivan is a products liability and commercial litigator, having authored articles on mass torts and securities litigation and presented on trial advocacy. He is experienced in mass tort litigation, with a particular emphasis on scientific and regulatory issues, as well as having experience in complex commercial, securities class action and corporate governance litigation. He is a partner in the Princeton office of Dechert LLP and can be reached at john.sullivan@dechert.com.
Eric L. Alexander is a partner in Reed Smith’s Washington office. He has spent almost his entire career representing drug and device companies in product liability litigation from discovery through motions, trials, and appeals, usually on the right side of the v. He is particularly interested in medical and proximate cause and the intersection of actual regulatory requirements and the conduct that plaintiffs allege was bad, which covers quite a bit. He can be reached at ealexander@reedsmith.com.
Melissa A. Wojtylak is a litigator who devotes most of her practice to representing life sciences industry clients in products liability and commercial matters, but she has been known to moonlight as a financial services litigator. She is of counsel in Reed Smith’s Philadelphia and Princeton offices and can be reached at mwojtylak@reedsmith.com.
Mark Herrmann Blogger Emeritus. October 28, 2006 to December 16, 2009.
1 comment:
Small point - However the USC decides Kent, Michigan's so-called "fraud exception" was meaningless. As worded, it requires both (a) a finding of intentional (e.g., felony) misrepresentation and (b) drug withdrawal directly linked with that finding.
There has not been a single case in the past twenty-five years that meets both criteria. As FDA's own amicus emphasizes in Kent, FDA favors a wide range of responses when fraud is suspected or fully uncovered - settling with company through a monetary fine and without pursuing prosecution, a label change, or some sort of warning/remedial program. None of these circumstances satisfy either condition. Nor (obviously) do they satisfy both.
As is well known, there is also a "would have been withdrawn" phrasing in Michigan's law had the intentional suppressed or mispresented facts been known. This bit is definitively impossible to litigate since no agency knows, or has a body which could decide, what it "would have done" under X, Y, Z circumstances. Thus, the writers of the Michigan law - whatever else one may say - were not the brightest bulbs in the state. FDA's inability to determine what it "might have done" - as well as its disinclination to be a "gatekeeper" to civil action - is also much emphasized in its amicus.
Thus, this decision is much more likely to impact fraud findings in states in which state court findings of fraud are a condition for punitive damages - famously, New Jersey - than Michigan.
Post a Comment